Try our Advanced Search for more refined results
Life Sciences - April, 2019
321 articles
- Keryx Investors Seek Class Cert. In Kidney Drug Stock Case
- G&E, Saxena White Win Lead In Nerve-Repair Investor Suit
- Monsanto Expert Testifies Roundup Is Safe Without Gloves
- Senators Float Bill To Make FTC Study Pharmacy Managers
- FDA Slaps Black Box Warning On Ambien, Other Sleep Drugs
- EPA Reaffirms Glyphosate Safety, Proposes Usage Changes
- DOJ Denies 'Antipathy' For FCA Whistleblower Co.
- Pay-For-Delay Ban, Other Drug Price Bills Advance In House
- With Opioid Charges, DOJ Signals Compliance Fixation
- FDA Allows Philip Morris To Market Tobacco 'Heatsticks'
- Pharma Co. Inks $17.5M Deal To End FCA Kickback Suit
- 2nd Circ. Affirms Toss Of Endo Securities Class Action
- Colgate Offered 'Sham Witness' In ERISA Suit, Workers Say
- Pa. Judge Doubts Conflict In Attys' Dual Level Opioid Work
- REIT, Biotech And Tech Startups Launch IPOs Totaling $215M
- AI Is Forcing FDA Medical Device Rules To Evolve
- Missing Elements From New Cannabis Banking Bill
- Monsanto Expert 'Micro-Analyzed' By Atty At Roundup Trial
- Endo Not Liable In Pa. For Defective Mesh Made By Subsidiary
- FDA Stalling On Impulsivity Warnings For Drugs: Nonprofit
- Pfizer Exec Seeks Justices' Take On ERISA Venue Selection
- BakerHostetler Snags Ex-Dinsmore IP Partner In DC
- Medtronic Can't Get Fed. Circ. Redo On $24M Spine IP Loss
- NECC Pharmacists Not At Fault For Fake Orders, Jury Hears
- 7 Cos. Heat Up IPO Pipeline With Nearly $1B In Deals
- Filing For Bankruptcy To Manage Opioid Suits Is No Magic Pill
- A Chat With Cleary Chief Talent Officer Hy Pomerance
- J&J Talc Supplier Argues For Its Future Claims Rep Choice
- Atty Sanctions Axed In Opioid MDL, Allowing Doc's Testimony
- DOJ Asks 7th Circ. To Revive Becton Price-Fixing Suit
- Bayer CEO Says Company Faces 13,400 Roundup Suits
- Del. Judge Tosses Bard's $67.5M Vascular Port IP Case
- Fed. Circ. Upholds Eli Lilly's Alimta Vitamin Regimen IP
- 11 Firms To Guide 7 IPOs Exceeding $1B To Start May
- Feds Likely To Try Again If Insys Jury Deadlocks
- FDA's Risk Evaluation Guidance Brings Clarity, Not Solutions
- Forced Arbitration Is A Far Worse 'Product' Than Jury Trials
- Bayer Is Still Fighting 'Flanax,' More Than A Decade Later
- Biotech Co. Faces Investor Suit Over 'Misleading' Merger Info
- Scrutiny Of Physician-Owned Distributors Is Far From Over
- Preet Bharara On The Human Factor In The Justice System
- Monsanto Faces Uphill Fight In Axing Punitives From Trial
- Opioid MDL Attys' Concealment Merited Sanction: Drug Cos.
- TridentUSA Ch. 11 Plan Faces Early, Multipronged Opposition
- J&J Trashes 'Radical' Okla. Opioid Case As Trial Looms
- Novartis Settles Suit Saying Janssen Maligned Rival Drug
- Kimberly-Clark Whistleblower Seeks Revival Of Axed FCA Suit
- Okla. Cities Not Bound By Purdue's Opioid Deal, Judge Says
- PacBio DNA Patent Suit Survives Dismissal Push
- Whistleblower Won't Get Atty-Client Docs In Debt Deal Suit
- OFCCP Case Changes The Game For Contractor Pay Audits
- Skadden, Latham Steer 2 Follow-On Offerings Raising $152M
- GSK Plans $100M Mont. Vaccine Production Site Expansion
- GTx Shareholder Sues To Block Oncternal Merger
- Competitive Generic Therapy Exclusivity Offers Benefits
- Astellas, Amgen To Pay $125M To End Kickback Probe
- J&J, Colgate's Talc Cancer Link 'Makes Sense,' Jury Told
- Monsanto Appeals $78.5M Loss In First Roundup Trial
- FTC Accuses Electronic Prescription Co. Of Monopolization
- After 10 Days Of Jury Silence, Insys Exec Asks To Go Home
- Philly Jury Slams J&J With $120M Award In Mesh Injury Case
- Investor Sues Boston Scientific Over FDA's Mesh Product Pull
- FDA Urged To Crack Down On Anti-Smoking Supplements
- Gene Therapy Co. Hit With Suit Over $877M Sale To Biogen
- Drug Lobby Says Athena Ruling May Zap Biotech Funding
- Colgate Tells Jury In Talc Cancer Trial Its Mines Asbestos-Free
- What Drove DOJ's 1st Opioid Distributor Charges?
- Jury Trials, Though In Decline, Are Well Worth Preserving
- Amazon Gets Customer's Walker Injury Suit Trimmed
- Allergan Drug Buyers Take One Last Shot At Class Cert.
- Big Biz Universally Beefing Up Compliance Units, KPMG Finds
- Synergy Pharmaceuticals Wins Ch. 11 Plan Approval
- J&J, Bausch Reach Talc Litigation Deal
- Cooley-Led Biotech Nixes IPO, Scores $142M Funding Round
- Ex-Aveo CFO Says Securities Fraud Verdict Should Be Tossed
- Pet Medicine Cos.' Suit To Block Rivals' Tie-Up Tossed
- A Broader View Of The US Supreme Court Bar
- Ex-Shkreli Atty Splitting Hairs Over 'Duty,' Gov't Says
- Diplomat Pharmacy Inks $14M Deal In Suit Over PBM Fees
- PE Firm Plugs $100M Into Medical Imaging Co. NorthStar
- DOJ Unveils 1st Criminal Charges Against Opioid Distributor
- J&J And Colgate Face Latest Talc Trial Together In Calif.
- Feds Seek Pause Of SEC's Civil Suit Against Theranos Official
- J&J Settles Wash. AG's Pelvic Mesh Case Just Before Trial
- Aveo Pharma Stock-Drop Suit Lands In Massachusetts
- Pfizer VP Returns To DLA Piper As Litigation Partner In DC
- Deals Rumor Mill: Dassault, Cerberus, Bain
- Insurers Seek To Lift Stay Amid J&J Talc Injury Suits
- J&J Butter Buyers Denied Cert. In 'No Trans Fat' Labeling Suit
- 4 Firms Seek To Lead Ranbaxy Antitrust MDL In Boston
- 4 Cos. Launch IPOs Totaling $650M Led By Mobile Games Biz
- Inside DOJ's Recent Charitable Copay Foundation Settlements
- Philly The Proper Venue For Kratom Death Case, Judge Rules
- New USPTO Guidance May Help Diagnostics Patents
- 15 Minutes With AbbVie's Chief Legal Officer
- Fed. Circ. Affirms PTAB Ax Of Hologic Medical Device Patent
- US Trustee Fights Bid To Seal Worker Info In 'Superbug' Ch. 11
- Meet The 'Wonder Drug' Drawing FDA Fire
- Blue Cross Attacks Janssen Prostate Cancer Drug 'Monopoly'
- J&J Says 2,400 Talc Suits Belong In Del. Federal Court
- J&J Win Shows Potential Limit To Mesh Injury Claims
- Opioid MDL Shouldn't Hold Up NJ County's Suit, Court Told
- X-Ray Engineer Gave Trade Secrets To Rival, Philips Says
- In Virtual Teams For Mass Torts, The 'Law Team' Is Critical
- Takeaways From DOJ Action Against Telemedicine Fraud
- McKesson To Pay $1.6M In Back Wages, Benefits, DOL Says
- Answers To AI Patent Questions May Be Found In Biotech
- Polsinelli Adds Boston Biotech IP Attys From Wolf Greenfield
- 5 Tips For Lawyers Entering The Cannabis Industry
- Health Hires: DLA Piper, McDermott, Barnes & Thornburg
- 5 Times Lawyers Settled During The Big Show
- Doc Linked To Insys Denies New Charges In Patient's Death
- Postpone Opioid MDL Trial? Get Real, Judge Says
- USPTO Patent Eligibility Rejections Fall Under New Guidance
- Breaking Down 3 New Senate Bills Targeting Drug Prices
- Deals Rumor Mill: Ancestry, Advent, Acuris
- AmerisourceBergen Investors Demand Opioid Crisis Records
- Lathrop Gage Nabs IP Pro From Sunstein Kann
- PE-Backed Medical Tech Co. Files Simpson Thacher-Led IPO
- The Big Picture: How #MeToo Is Changing The Legal Industry
- Jury Trials Are In Decline For Good Reason
- Atty Fees, Costs Approved in $3.3M Lion Biotech Deal
- AutoMedx Says Zoll's $5.4M Suit Is Barred By Bankruptcy
- Genetic Testing Is On FTC's Radar
- Fidelity Brokerage Immune From Market Case: 1st Circ.
- EPA Approved Roundup Based On Bogus Studies, Jury Told
- Insurance Co. Wants To Depose Retired Judge In Stryker Row
- Neovasc Will Add CardiAQ Founders To Patents To End Suit
- Feds Slam Order To Cough Up Info In Kickbacks Suit
- Fed. Circ. Keeps PTAB Ax Of Purdue OxyContin Patent Claims
- Escape Hatch Remains For Judges Accused Of Misconduct
- DOJ Dismissal Power Looking Wobbly In FCA Cases
- Cancer Biotech, 2 Others Score IPOs Totaling $279M
- Celgene Wants Sun Pharma's Revlimid Generic Blocked
- Justice Dept. Charges 60 In Appalachia Opioid Sweep
- BioPharma Firm, Device Maker Blocked Generic, Sandoz Says
- UK Spots Issues With Thermo Fisher $925M Microscope Deal
- Attys Re-Up Bid To Drop Avenatti From $450M Class Action
- Biologic Manufacturers Should Expect Antitrust Scrutiny
- Federal Courts' #MeToo Response Is A Guide For State Courts
- J&J Dodges Pelvic Mesh Claims In Philadelphia Trial
- Few Avenues To Protection For Foreign FCPA Whistleblowers
- 'Superbug' Pharma Firm Seeks Quick OK On Ch. 11 Bonuses
- Riding #MeToo Wave, State Courts Get Their Ships In Order
- Bayer Exec Denies Knowing Of Ghostwriting At Roundup Trial
- EEOC's Lipnic On Sexual Harassment In The Courthouse
- CVS To Pay $535K To End Allegations Of Bogus Percocet Rx
- Ex-Theranos CEO Says Feds Are Stonewalling Over Docs
- J&J's Rush To Market Made Mesh Patients Suffer, Jury Told
- Opioid MDL Attys Say Sanction 'Does Not Fit The Crime'
- FDA Orders Surgical Mesh Products Pulled From US Market
- Why I Became A Lawyer: A Circuitous Path To The Law
- Cooley-Led Tech Unicorn, Biotech Firm Raise IPO Targets
- Wilson Sonsini Adds Life Sciences Veterans From Arent Fox
- 4 Tips For Global Patient Support Compliance: Part 2
- Indirect Buyers Can't Bring Antitrust Suit, Dental Cos. Say
- Zoll Says Ex-Partners Can't Escape $5M Arbitration Award
- Trade Secrets Suit Against Mitsui Severely Trimmed
- DOJ Sees 'Arbitrary' FCA Dismissal Bid Rejected
- Discipline Rare For State Judges In Sexual Misconduct Cases
- Wall Of Secrecy Surrounds Sexual Harassment In State Courts
- Judge Will Let Cameras Roll In Okla. Opioid Trial
- High Court Gives Thumbs-Down To 3 Employment Cases
- Channel CEO Stunned At Boston Scientific's Deal Rebuff
- 9 Companies File IPOs To Bolster May Pipeline
- Tainted Scopes Related To 3 More Deaths, FDA Says
- Deals Rumor Mill: AB InBev, Chi-Med, Biohaven Pharma
- Judging A Book: Conrad Reviews 'The Jury Crisis'
- 'Superbug'-Fighting Pharma Firm Hits Ch. 11 With Sale Plans
- 5th Circ. Upholds 3-Year Medicaid Ban For 2 Texas Docs
- High Court Passes On Tribal Immunity, Alice Timing, 'Empire'
- Mass. Judge Upholds Convictions For 2 NECC Pharmacists
- 4 Firms Spearhead $1.2B Catalent-Paragon Bioservices Deal
- Insys CEO Resigns Amid Uncertain Future
- Robocall Damages Against Marketer Could Hit $925M
- Adult Diaper Co. Must Pay For Worker Retaliation In FCA Suit
- 15 Firms To Steer Robust IPO Lineup Led By Pinterest
- Zimmer Biomet Investors Seek Class Cert. In Stock-Drop Suit
- Allergan Drug Buyers' Renewed Bid For Cert. Deemed 'Futile'
- Texas Senate Passes Bill Cracking Down On Legal Ads
- Teva, J&J Face Opioid Trial In 'Unreasonably Small' Courtroom
- Allergan, St. Regis Ask Justices To End 'Blocking Patent' Rule
- Asbestos Experts Were Cut For 'Parroting' Others, Judge Says
- Judge Won't Certify Perrigo's Appeal In Drug Price-Fixing MDL
- No Shortage Of Opinions On New USPTO Eligibility Guidance
- Cannabis Banking Bill Is Promising, But Limited In Scope
- Bristol-Myers Wins Investor Support For $74B Celgene Buy
- Med Device Biz Investor Ajax Scores $85M In Funding Push
- Revamping Your Approach To Client Development
- Monsanto Tested Roundup Using 'Dumb' Assumptions: Expert
- Trump Admin Moves To Rein In Agency Guidance Materials
- U.S. Trustee Takes Aim At Imerys' Ch. 11 Asbestos Claims Rep
- 5 Things To Watch As Indivior Attacks DOJ Opioid Indictment
- Pa. Panel Backs Woman's $13.5M J&J Mesh Injury Award
- 'Pharma Bro' Shkreli Can't Duck Kidney Drug Antitrust Suit Yet
- AbbVie To Settle With Shire Investors Over Failed $55B Tie-Up
- Jefferies Urges Court To End Investors' Suit, Sanction Attys
- FDA Seeks More Data On Hand Sanitizer Ingredient Safety
- 4 Tips For Global Patient Support Compliance: Part 1
- What Lawyers Must Know Before Acting As Escrow Agents
- Two Firms Steer Cybersecurity Software Co. To $108M IPO
- Who Can Be A Defendant In Biosimilar Patent Litigation?
- Bonuses, Debt Claims Probe OK'd In TridentUSA Ch. 11
- No More Trial Delays In Opioid MDL, Judge Says
- Sandoz Says Antitrust Row Can't Hinge On Drug Patent Case
- Pa. Justices To Mull Standing For Out-Of-State Mesh Patients
- FTC's Impax Decision Shows Hard Line On Reverse Payments
- Orrick Nabs Former Co-Chair Of MoFo's Life Sciences Group
- Acorda Asks Justices To Abolish 'Blocking Patent' Doctrine
- Johns Hopkins, Bristol-Myers Want Sanctions In Syphilis Suit
- Deals Rumor Mill: VW, QSR Brands, BioTek
- McGuireWoods Snags Ex-Faegre Health Pro
- FTC Makes $25M Deals With 'Viagra For Your Brain' Sellers
- Plan Sponsors Should Beware Hidden Costs From PBMs
- Tax-Dodging Exec's Hail Mary Bid For Less Prison Time Fails
- Execs, MDs Charged In $1.2B Medicare Fraud Scheme
- Roundup's Link To Cancer 'Not A Hard Call,' Jury Hears
- Ex-Attys Seek To DQ New Counsel Handling $350M Shire Deal
- FDA Exclusivity View Blocking Opioid Treatment, Suit Says
- Indivior Indicted Over Opioid Treatment Marketing Fraud
- Ill. AG Is Latest To Sue Purdue Over Opioid Crisis
- Medical Supplier Dodges Spousal Bias Claims At 8th Circ.
- Dickinson Wright Adds Chemist-Turned-Patent Pro As Partner
- PTAB Axes Hair Loss Treatment Patent In Incyte Challenge
- Opana Buyers Seek Class Cert. In Pay-For-Delay Row
- The Biggest Deals From Q1 & The Firms That Led Them
- Freelance Attorneys Are An Asset To In-House Legal Teams
- Real Estate Rumors: Ventas, SDG, Copart Of Connecticut
- Synergy Shareholders End Ch. 11 Objections For $1.4M
- Don't Discount Drug Discounting
- CBD Scrutiny May Signal Broader FDA Enforcement Trend
- Athena Asks Fed. Circ. To Rethink 'Evisceration' Of Patent Law
- Cancer Risk Doubles With Regular Roundup Use, Jury Told
- Janssen Needn't Show Earnings In Off-Label Use Suit
- Opioid MDL Attys Sanctioned For Hiding Doctor's Cooperation
- 5th Circ. Nixes 'Obamacare' Brief To Avoid Judge's Recusal
- Bio-Rad Cleared To Enforce Sample Protection Patents
- 4 Recent Fed. Circ. Decisions Patent Attorneys Need To Know
- Thermo Fisher's $4.7M Wage Deal Gets Green Light
- 9th Circ. Won't Rehear Bio-Rad Ex-GC's $8M Win
- Tech 'Unicorn' Tops 4 IPO Launches With $626M Deal
- Concordia Pharma Sues Over Bowel Drug Trade Secrets
- BakerHostetler Can't Overturn Opioid MDL Disqualification
- Former FDA Drug Regulatory Adviser Joins Covington In DC
- J&J's Mesh Appeal Nothing But A 'Trial Balloon,' 7th Circ. Told
- Calif. Jury Finds No Asbestos In J&J Talc
- Cancer Center's $7.2M Antitrust Deal Flawed, Court Says
- Apotex Can't Sink Amgen's IP Suit Over Drugs To Aid Chemo
- Outgoing HHS Watchdog Targeted Purdue, Paved ACA's Path
- 'Massive Scheme' Or 'Big Lie'? Insys Execs In Jury's Hands
- Pa. Stuck In Litigation Limbo As Purdue Inks 1st Opioid Deal
- Pfizer's Lyrica Update Infringes Patent, Sun Pharma Says
- Ex-Ranbaxy Owners Face Contempt Over $506M Award
- Justices Urged To Pass On Orexigen Disclosure Dispute
- OFCCP Case Sheds Light On Pay Equity Analysis Techniques
- Unanswered Questions On FDA-USDA Cell Culture Agreement
- 3rd Circ. Hands J&J Win In Applicant's Background Check Suit
- TridentUSA Creditors Clash In Pre-Bankruptcy Debt Probes
- Insys Wants Anthem Fentanyl Suit Sent To Ohio Opioid MDL
- Insys Execs Put 'Profits Over Patients,' Feds Tell Jury
- Judge Won't Stop Roundup Ads Allegedly Targeting Jury Pool
- Chancery OKs $9M Deal In Fight For Med Device Co.
- Big Opioid Case Trimmed To Beat Drugmaker 'Stall Tactics'
- PE-Backed Tradeweb Tops 3 IPOs With $1.1B Offering
- Deals Rumor Mill: Deutsche Bahn, ICG, Apotex
- DOJ Must Explain FCA Dismissals, Judge Rules
- Fed. Circ. Agrees Purdue's OxyContin Patent Is Obvious
- Fed. Circ. Ruling Clarifies Role Of USPTO Eligibility Guidance
- What High Court's Expansion Of FCA Time Limits Would Mean
- Medical Device Co. Medacta Scores $1.9B In Swiss IPO
- Care.com Hit With Shareholder Suit Over Vetting Practices
- Pharma Cos. To Pay $123M To End Medicare Kickbacks Probe
- 'Big Tech' Questions Echo Early Days Of US Corporate Law
- The Important Reasons DOJ Wants To Toss Gilead FCA Case
- Expert In Roundup Trial Says Regulators Ignored Own Rules
- CVS Loses Challenge To Sentry's Revamped Antitrust Suit
- LA Times Owner 'Caught And Killed' Cancer Drug, Suit Says
- BakerHostetler Crossed 'Ethical Line' In Opioid MDL: Gov'ts
- Roche Evades Cancer Study Stock-Drop Suit For Second Time
- Fed. Circ. Ruling Shows Limits Of USPTO Eligibility Guidance
- Pa. Superior Court Clears Way For Out-Of-State Mesh Cases
- 1 Firm Edged Ahead In March As IPOs Finally Gain Steam
- Insys Judge Says Part Of Gov't Racketeering Case Is 'Thin'
- Bid To Drop Avenatti From Class Action Fails Over Procedure
- Roche Refiles For US Antitrust Review Of $4.3B Spark Buy
- Montel Williams Settles With CBD Cos. To End Likeness Row
- Ex-Abbott Labs Worker Gets 2nd Shot At Discrimination Claim
- Fed. Circ. Affirms WaveForm's Glucose Monitoring Patents
- Medical Pot Law Is Not A Right To Grow, Fla. Court Says
- House Says Private Email Off-Limits In Collins Case
- Purdue's Sackler Family Wants 'Divisive' Mass. Suit Tossed
- Deal Nets Fla. Medical Marijuana Provider Extra Dispensaries
- Ex-Insys VP Pays $9.5M To End Ariz. Opioid Kickback Claims
- FDA Issues Warnings Over CBD Claims, Sets Public Meeting
- Hospital Says Fed. Circ. Subverting Sanctity Of Jury Verdicts
- Okla. Cities Seek To Clarify $270M Deal In Purdue Opioid Case
- Key Opioid Case On 'Untenable' Course, Teva Says
- Insys Judge Unmoved So Far By Midnight Acquittal Bid
- Pa. Counties Want Out Of Coordinated Opioid Litigation
- Tribes Get Tentative Green Light In Opioid MDL
- Tribes Urge 5th Circ. To Preserve Indian Health Law In ACA
- Highlights From 2019 ABA Antitrust Spring Meeting: Part 2
- J&J, Other Drug Cos. Fail To Shake Fla. AG's Opioid Suit
- HHS Inspector General To Resign After 15 Years
- Invisalign Maker Strikes $35M Deal With Rival In IP Fight
- Novo Nordisk Investors Seek Cert. In Insulin Pricing Suit
- Kisor Case May Positively Disrupt Technological Governance
- Gibson Dunn Health Chair Tapped As Catholic U. Law Dean
- FDA Focus: What Latham's Practice Chair Is Watching
- NY, Fla. Buyers Get Cert. In Gerber Formula False Ad Suit
- BioPharma Co. Ducks Stock-Drop Suit Over Presentation Hype
- 2 Republican AGs Break Rank, Back ACA At 5th Circ.
- DOJ's Novartis Kickback Case Cleared For Trial
- Ligand Pushes Chancery To Squelch $4B Formula-Botch Suit
- High Court Again Refuses To Revisit FCA Materiality
- Judge Botched BakerHostetler DQ In Opioid MDL, Endo Says
- Insys Drug Was 'Amazing' For Pain, Patient Tells Jury
- FDA Looks To End Athenex's Active Ingredient Suit
- Highlights From 2019 ABA Antitrust Spring Meeting: Part 1
- Fed. Circ. Rules 2 Cleveland Clinic Test Patents Ineligible
- 3 Firms Steer $260M Deal For Migraine Drug Royalty Interest